Frequently Asked Questions

Next-Generation MSC (Mesenchymal Stem Cell) Therapy refers to an advanced manufacturing and selection process developed by Dr. Adas Darinskas and the team at Reverse Body Time. Unlike standard MSC preparations, Next-Gen MSCs are cultivated under strictly controlled conditions that preserve their full regenerative potential — resulting in cells with cells designed to preserve potency and viability throughout the manufacturing process. Standard stem cell therapies often use cells that have been expanded many times, reducing their effectiveness. The Next-Gen manufacturing process is designed to maintain cellular quality at every stage of production.

MSC therapies have a well-established safety profile, supported by thousands of clinical studies. Culturally expanded MSCs from umbilical cord tissue have low HLA cell surface markers, which research suggests makes these cells immunoprivileged and immunomodulatory — significantly reducing the chance of rejection. Because stem cells must be kept in a medium that allows them to survive — such as cord blood plasma, albumin, and DMSO for cryopreservation — a small number of people may experience a reaction to one of these carriers rather than to the cells themselves. Any sensitivities are discussed during the scientific consultation and protocols are adjusted accordingly. The most common side effects are mild and temporary — such as slight fatigue or localised discomfort at the injection site. All treatments are administered at Innovita Clinic in Vilnius by experienced medical professionals, with treatment design guided under our scientific and medical team's direction. A thorough scientific consultation is conducted before any treatment to assess your individual suitability and minimise risk.

Our treatments address a wide range of conditions including: neurological conditions (Alzheimer's, Parkinson's, ALS, MS, TBI, stroke recovery, autism spectrum disorder), autoimmune conditions (lupus, rheumatoid arthritis, Crohn's disease, Hashimoto's), musculoskeletal conditions (osteoarthritis, spinal conditions, joint injuries), hormonal optimisation (testosterone, menopause, PCOS, fertility), immune dysregulation (Long COVID, Lyme disease, chronic fatigue syndrome), oncology support, and longevity and performance optimisation. If your condition is not listed, please contact us — we evaluate each case individually.

Results vary depending on the condition being treated, the protocol used, and the individual patient. Some patients notice improvements within weeks of treatment, while for others — particularly those with chronic or degenerative conditions — the full therapeutic benefit may take 3 to 6 months to manifest as the cells continue to work at the cellular level. The scientific and clinical team will give you a realistic understanding of potential outcomes and expectations of timeline during your scientific consultation, based on your specific condition and protocol.

Yes — and in many cases, combining therapies produces significantly better outcomes than any single treatment alone. For example, combining Next-Gen MSC therapy with exosomes enhances the regenerative signal; adding peptide protocols supports the body's ongoing repair processes; and IV biologics create the optimal cellular environment for all therapies to perform at their best. Combined protocols are designed under our scientific and medical team's direction, specifically for clients whose conditions benefit from a multi-modal approach.

The journey has four clear steps: (1) Discovery Call — a complimentary conversation with Jed Ryan to understand your health goals and assess whether our treatments are a good fit; (2) Scientific Consultation — a comprehensive Zoom consultation where your case is reviewed by both the scientific team and the medical team at Innovita; (3) Protocol Design — a personalised treatment protocol developed under Dr. Darinskas's scientific direction, in collaboration with the treating medical team; (4) Treatment in Vilnius — you travel to Innovita Clinic in Vilnius, Lithuania, where your treatment is administered by expert clinicians. Follow-up support is provided throughout.

Yes — all treatments are administered at Innovita Clinic in Vilnius, Lithuania. Vilnius is easily accessible from most major European cities and has direct flights from many international hubs. We assist with all logistics including clinic scheduling, and can provide guidance on accommodation and travel arrangements. Most treatment visits require a stay of 3 to 7 days, depending on the protocol. Many patients find the experience of visiting Vilnius — a beautiful, historic European capital — to be a positive part of their overall journey.

Treatment costs vary depending on the type of therapy, the number of sessions, and the complexity of the protocol. Because every client receives a personalised protocol, pricing is discussed once the necessary consultations are complete and your case has been reviewed by our scientific and medical team. You will receive a full cost breakdown before committing to any treatment program. Please book a discovery call to begin the conversation.

The initial discovery call with Jed Ryan is complimentary. The scientific consultation with our team involves a fee, which will be communicated to you after your discovery call. This consultation is a comprehensive evaluation of your medical history, current health status, and treatment options — and is an essential step in ensuring that any protocol we recommend is safe and appropriate for your individual situation.

We will guide you through exactly what is needed during the intake process. Generally, we ask for recent blood work, any relevant imaging (MRI, X-ray, etc.), a list of current medications and supplements, and a summary of your medical history. The more information our scientific and medical team has in advance, the more precisely your protocol can be designed. We will send you a detailed checklist after your discovery call.

All MSCs and exosomes used in our protocols are manufactured by Reverse Body Time — an integrated research, GMP manufacturing, and clinical care operation based in Vilnius, Lithuania. Cells are sourced from ethically consented donors and processed under strict GMP (Good Manufacturing Practice) conditions. The manufacturing process is designed to maximise potency and purity while ensuring complete traceability and safety at every stage.

Regenerative medicine is a rapidly evolving field, and regulatory frameworks vary by country. Treatments are administered at Innovita Clinic in Lithuania, which operates within the European Union's regulatory framework for advanced therapy medicinal products (ATMPs). All treatments are conducted under medical supervision and in compliance with applicable regulations. We encourage patients to conduct their own due diligence and are happy to provide full transparency about the regulatory status of any treatment we offer.

Yes — MSC therapy, exosome therapy, and peptide protocols are all supported by extensive peer-reviewed scientific literature. MSC research alone encompasses thousands of published studies across a wide range of conditions. Our Science page provides curated links to key research papers for each treatment category. We believe strongly in scientific transparency and encourage all patients to review the evidence base before making any treatment decisions.

Yes. Many of our clients travel from the United States. Treatment is administered at Innovita Clinic in Vilnius under Lithuanian License 4094. We coordinate the full journey including pre-treatment consultation with Dr. Adas Darinskas, treatment scheduling, and post-treatment follow-up. US patients typically combine treatment with a 5–10 day stay in Vilnius depending on the protocol.

Yes. Strong Craft Regen is based in Ontario, Canada, and coordinates Canadian patients to receive treatment at Innovita Clinic in Vilnius. Cell therapies are regulated differently in each jurisdiction — in Canada, most cell therapies remain investigational and require Health Canada authorization for domestic administration. Patients who choose to receive treatment internationally do so under the regulatory framework of the country where treatment is administered, in this case Lithuania and the European Union.

Lithuania is a European Union member state, and Innovita Clinic operates under EU medical regulations and Lithuanian License 4094. For European patients, Vilnius is typically a short flight away, and treatment can often be completed within a 3–7 day stay depending on the protocol. We coordinate scheduling, travel logistics, and pre- and post-treatment communication.

Length of stay depends on the protocol. IV-based treatments and peptide protocol initiation typically require 2–4 days. Joint or spinal injection protocols typically require 4–7 days to allow for pre-treatment assessment, treatment, and post-treatment monitoring. Combined or multi-stage protocols may require 7–10 days. We confirm the exact stay length with you during the consultation phase.

We typically request: a current medical history summary, recent bloodwork (within the last 6 months where possible), imaging reports relevant to your condition (MRI, CT, X-ray as applicable), a list of current medications and supplements, and any prior specialist reports. We provide a personalised records checklist after your discovery call so you know exactly what to send.

Innovita Clinic operates under Lithuanian License 4094, which is publicly verifiable through Lithuanian medical regulatory channels. Dr. Adas Darinskas is a treating physician at Innovita Clinic and Chief Science Officer at Reverse Body Time, the research and manufacturing partner that produces the MSC, exosome, and peptide therapies used. We are happy to provide additional credential verification information on request.

Follow-up varies by protocol. For most patients we maintain direct communication for protocol adjustments, peptide reorders, and any questions. For patients on multi-month peptide or biologic protocols, products are shipped directly to your home address. For post-treatment medical follow-up requiring in-person assessment, we recommend coordinating with your local physician and we can provide treatment summaries to share with them.

Regulatory status varies. In the United States, the FDA has not approved most MSC or exosome products outside specific contexts such as umbilical cord blood for blood disorders. In Canada, most cell therapies are considered investigational by Health Canada. In the European Union, advanced therapy medicinal products are regulated by the European Medicines Agency, and treatment in Lithuania is administered under EU and Lithuanian medical regulation. Patients who choose to receive treatment internationally do so under the regulatory framework of the country of treatment.